Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization
Autor(a) principal: | |
---|---|
Data de Publicação: | 2003 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFBA |
Texto Completo: | http://repositorio.ufba.br/ri/handle/ri/17525 |
Resumo: | Texto completo: acesso restrito. p. 1453–1468 |
id |
UFBA-2_efaa94836c272a131820e13009324ea5 |
---|---|
oai_identifier_str |
oai:repositorio.ufba.br:ri/17525 |
network_acronym_str |
UFBA-2 |
network_name_str |
Repositório Institucional da UFBA |
repository_id_str |
1932 |
spelling |
Corrêa, João CarlosBadaró, Roberto José da SilvaBumroongkit, ChaiwatMera, Jorge RaúlDolmann, Alberto LorenzoMartínez, Luis Guillermo JuárezMayrinck, Lusane RomeroTamez, RicardoYang, Joanna Y.Corrêa, João CarlosBadaró, Roberto José da SilvaBumroongkit, ChaiwatMera, Jorge RaúlDolmann, Alberto LorenzoMartínez, Luis Guillermo JuárezMayrinck, Lusane RomeroTamez, RicardoYang, Joanna Y.2015-05-04T15:33:10Z20030149-2918http://repositorio.ufba.br/ri/handle/ri/17525v. 25, n. 5Texto completo: acesso restrito. p. 1453–1468Background: Empiric therapy for community-acquired pneumonia (CAP) requires the use of antibiotics with activity against a broad spectrum of respiratory pathogens and suitable pharmacokinetic properties to simplify IV-to-oral step-down therapy switches. Objective: The aim of this study was to compare the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin with a standard regimen of IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin in patients with mild to moderate CAP requiring hospitalization. Methods: In a randomized, open-label, parallel-group, multicenter study, adults with CAP received 7 to 14 days of treatment with either IV gatifloxacin 400 mg QD with the stepdown option or IV ceftriaxone 1 or 2 g QD (with or without erythromycin 0.5 or 1 g QID or clarithromycin 500 mg BID) with the stepdown option. Results: One hundred seventy adults with CAP were included in the study. IV gatifloxacin was stepped down to oral gatifloxacin in 90.6% (View the MathML source) of patients; IV ceftriaxone was stepped down to oral clarithromycin in 87.1% (View the MathML source) of patients. Among clinically evaluable patients (n = 153), cure rates at 1 to 3 days after treatment were 97.4% in the gatifloxacin group (View the MathML source) and 90.9% in the ceftriaxone group (View the MathML source), with a 95% CI for the difference (−3.7% to 19.1%) indicating statistical equivalence. In patients in whom pathogens were isolated from pretreatment sputum cultures, bacteriologic eradication rates were 100.0% (View the MathML source) and 90.9% (View the MathML source), respectively. Both regimens were well tolerated; treatment-related adverse events occurred in 27.1% (View the MathML source) and 21.2% (View the MathML source) of patients, respectively. Conclusions: In the population studied, treatment with IV gatifloxacin with an option for oral stepdown gatifloxacin was as effective for achieving clinical cure as IV ceftriaxone (with or without concomitant IV erythromycin or clarithromycin) with an option for oral stepdown clarithromycin. Both regimens were well tolerated.Submitted by Edileide Reis (leyde-landy@hotmail.com) on 2014-01-08T12:17:40Z No. of bitstreams: 1 Roberto Badaró.pdf: 1206906 bytes, checksum: 3a95cd2750f59092c68ccd4d1f0e9c09 (MD5)Approved for entry into archive by Flávia Ferreira (flaviaccf@yahoo.com.br) on 2015-05-04T15:33:10Z (GMT) No. of bitstreams: 1 Roberto Badaró.pdf: 1206906 bytes, checksum: 3a95cd2750f59092c68ccd4d1f0e9c09 (MD5)Made available in DSpace on 2015-05-04T15:33:10Z (GMT). No. of bitstreams: 1 Roberto Badaró.pdf: 1206906 bytes, checksum: 3a95cd2750f59092c68ccd4d1f0e9c09 (MD5) Previous issue date: 2003http://dx.doi.org.ez10.periodicos.capes.gov.br/10.1016/S0149-2918(03)80132-7reponame:Repositório Institucional da UFBAinstname:Universidade Federal da Bahia (UFBA)instacron:UFBAGatifloxacinCeftriaxoneClarithromycinErythromycinCerythromycinCommunity-acquired pneumoniaTolerabilityRandomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalizationClinical Therapeuticsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article10000-01-01Brasilinfo:eu-repo/semantics/openAccessengORIGINALRoberto Badaró.pdfRoberto Badaró.pdfapplication/pdf1206906https://repositorio.ufba.br/bitstream/ri/17525/1/Roberto%20Badar%c3%b3.pdf3a95cd2750f59092c68ccd4d1f0e9c09MD51LICENSElicense.txtlicense.txttext/plain1345https://repositorio.ufba.br/bitstream/ri/17525/2/license.txtff6eaa8b858ea317fded99f125f5fcd0MD52TEXTRoberto Badaró.pdf.txtRoberto Badaró.pdf.txtExtracted texttext/plain40586https://repositorio.ufba.br/bitstream/ri/17525/3/Roberto%20Badar%c3%b3.pdf.txtaec48a8ac14db6ac1b17ab2a15505e6eMD53ri/175252022-08-08 13:17:47.633oai:repositorio.ufba.br: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Repositório InstitucionalPUBhttp://192.188.11.11:8080/oai/requestopendoar:19322022-08-08T16:17:47Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)false |
dc.title.pt_BR.fl_str_mv |
Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization |
dc.title.alternative.pt_BR.fl_str_mv |
Clinical Therapeutics |
title |
Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization |
spellingShingle |
Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization Corrêa, João Carlos Gatifloxacin Ceftriaxone Clarithromycin Erythromycin Cerythromycin Community-acquired pneumonia Tolerability |
title_short |
Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization |
title_full |
Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization |
title_fullStr |
Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization |
title_full_unstemmed |
Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization |
title_sort |
Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization |
author |
Corrêa, João Carlos |
author_facet |
Corrêa, João Carlos Badaró, Roberto José da Silva Bumroongkit, Chaiwat Mera, Jorge Raúl Dolmann, Alberto Lorenzo Martínez, Luis Guillermo Juárez Mayrinck, Lusane Romero Tamez, Ricardo Yang, Joanna Y. |
author_role |
author |
author2 |
Badaró, Roberto José da Silva Bumroongkit, Chaiwat Mera, Jorge Raúl Dolmann, Alberto Lorenzo Martínez, Luis Guillermo Juárez Mayrinck, Lusane Romero Tamez, Ricardo Yang, Joanna Y. |
author2_role |
author author author author author author author author |
dc.contributor.author.fl_str_mv |
Corrêa, João Carlos Badaró, Roberto José da Silva Bumroongkit, Chaiwat Mera, Jorge Raúl Dolmann, Alberto Lorenzo Martínez, Luis Guillermo Juárez Mayrinck, Lusane Romero Tamez, Ricardo Yang, Joanna Y. Corrêa, João Carlos Badaró, Roberto José da Silva Bumroongkit, Chaiwat Mera, Jorge Raúl Dolmann, Alberto Lorenzo Martínez, Luis Guillermo Juárez Mayrinck, Lusane Romero Tamez, Ricardo Yang, Joanna Y. |
dc.subject.por.fl_str_mv |
Gatifloxacin Ceftriaxone Clarithromycin Erythromycin Cerythromycin Community-acquired pneumonia Tolerability |
topic |
Gatifloxacin Ceftriaxone Clarithromycin Erythromycin Cerythromycin Community-acquired pneumonia Tolerability |
description |
Texto completo: acesso restrito. p. 1453–1468 |
publishDate |
2003 |
dc.date.issued.fl_str_mv |
2003 |
dc.date.accessioned.fl_str_mv |
2015-05-04T15:33:10Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://repositorio.ufba.br/ri/handle/ri/17525 |
dc.identifier.issn.none.fl_str_mv |
0149-2918 |
dc.identifier.number.pt_BR.fl_str_mv |
v. 25, n. 5 |
identifier_str_mv |
0149-2918 v. 25, n. 5 |
url |
http://repositorio.ufba.br/ri/handle/ri/17525 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.country.fl_str_mv |
Brasil |
dc.source.pt_BR.fl_str_mv |
http://dx.doi.org.ez10.periodicos.capes.gov.br/10.1016/S0149-2918(03)80132-7 |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFBA instname:Universidade Federal da Bahia (UFBA) instacron:UFBA |
instname_str |
Universidade Federal da Bahia (UFBA) |
instacron_str |
UFBA |
institution |
UFBA |
reponame_str |
Repositório Institucional da UFBA |
collection |
Repositório Institucional da UFBA |
bitstream.url.fl_str_mv |
https://repositorio.ufba.br/bitstream/ri/17525/1/Roberto%20Badar%c3%b3.pdf https://repositorio.ufba.br/bitstream/ri/17525/2/license.txt https://repositorio.ufba.br/bitstream/ri/17525/3/Roberto%20Badar%c3%b3.pdf.txt |
bitstream.checksum.fl_str_mv |
3a95cd2750f59092c68ccd4d1f0e9c09 ff6eaa8b858ea317fded99f125f5fcd0 aec48a8ac14db6ac1b17ab2a15505e6e |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA) |
repository.mail.fl_str_mv |
|
_version_ |
1808459468543885312 |